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Abstract
Introduction: Stenotrophomonas maltophilia is acquiring increasing importance as a nosocomial pathogen.
Methods: We retrospectively studied the characteristics and outcome of patients with any type of S. maltophilia infection at
the University Hospital of Heraklion, Crete, Greece, between 1/2005–12/2010. S. maltophilia antimicrobial susceptibility was
tested with the agar dilution method. Prognostic factors for all-cause in-hospital mortality were assessed with multivariate
logistic regression.
Results: Sixty-eight patients (median age: 70.5 years; 64.7% males) with S. maltophilia infection, not related to cystic fibrosis,
were included. The 68 patients were hospitalized in medical (29.4%), surgical (26.5%), hematology/oncology departments
(23.5%), or the intensive care units (ICU; 20.6%). The most frequent infection types were respiratory tract (54.4%),
bloodstream (16.2%), skin/soft tissue (10.3%), and intra-abdominal (8.8%) infection. The S. maltophilia-associated infection
was polymicrobial in 33.8% of the cases. In vitro susceptibility was higher to colistin (91.2%), trimethoprim/sulfamethoxazole
and netilmicin (85.3% each), and ciprofloxacin (82.4%). The empirical and the targeted treatment regimens were
microbiologically appropriate for 47.3% and 63.6% of the 55 patients with data available, respectively. Most patients
received targeted therapy with a combination of agents other than trimethoprim/sulfamethoxazole. The crude mortality
and the mortality and the S. maltophilia infection-related mortality were 14.7% and 4.4%, respectively. ICU hospitalization
was the only independent prognostic factor for mortality.
Conclusion: S. maltophilia infection in a general hospital can be associated with a good prognosis, except for the patients
hospitalized in the ICU. Combination reigmens with fluoroquinolones, colistin, or tigecycline could be alternative treatment
options to trimethoprim/sulfamethoxazole.
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Introduction
Stenotrophomonas maltophilia is a motile, aerobic, glucose non-
fermenting, non-sporulating, Gram-negative bacillus [1,2]. It can
be isolated from various sources in nature, including water, soil,
plants, and animals. S. maltophilia is primarily an opportunistic
human pathogen, causing nosocomial infections in immunocom-
promised or debilitated patients [3]. It can adhere to moist foreign
surfaces and form biofilms. It can thus colonize the inanimate
hospital environment and the devices used for patient care [4].
The nosocomial S. maltophilia infections are typically polyclonal in
origin, except for those acquired in the intensive care unit [ICU]
[5]. The main types of infections associated with S. maltophilia
include pneumonia, bloodstream infections, as well as urinary tract
infections, intra-abdominal infections, meningitis, and ocular
infections [1]. In patients with cystic fibrosis, S. maltophilia can
colonize the airways and be associated with acute pulmonary
exacerbations [6].
S. maltophilia infections are acquiring increasing importance in
the hospital environment, as the size of the susceptible patient
population increases [7,8]. The treatment of S. maltophilia can be
problematic. This pathogen is characterized by intrinsic resistance
to multiple classes of antibiotics, owed to various mechanisms such
as decreased permeability, production of b-lactamases and of
aminoglycoside modifying enzymes, or the presence of multidrug
efflux pumps [9]. Resistance can also emerge during therapy [10].
In this context, we sought to study the clinical and microbiological
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37375characteristics, as well as the treatment outcome of patients with S.
maltophilia infection in a general hospital.
Methods
Study population
All patients during a 6-year period (Jan 2005–Dec 2010) who
provided a culture specimen from which S. maltophilia grew were
identified retrospectively through the electronic database of the
microbiological laboratory of the University Hospital of Herak-
lion, Crete, Greece. The study hospital is a general, tertiary-care
center, with a 680-bed capacity (including an 11-bed ICU). All of
the available medical records of the candidate for inclusion
patients were retrieved and reviewed. Those patients in whom the
S. maltophilia isolate was associated with infection were included in
the study. Infection versus colonization was differentiated in
accordance to the CDC definitions for nosocomial infection
surveillance [11]. For patients who had more than one episodes of
infection with S. maltophilia, only the first episode was analyzed in
our study.
Data extraction
The clinical data extracted for each patient included: demo-
graphic characteristics, department of hospitalization, comorbid-
ity, duration of hospitalization, type of infection attributed to S.
maltophilia, outcome of infection, all-cause in-hospital mortality,
and infection-related mortality. The microbiological data extract-
ed included: type of culture specimen, number of positive cultures
with S. maltophilia, other pathogens isolated in the same as S.
maltophilia culture specimen or in additional culture specimens
during the course of the same episode of infection.
Definitions
Malnutrition was defined as a body mass index ,18.5 Kg/m
2,
unintentional weight-loss over 5% of body weight during the last
month, or over 10% during the last 6 months. Trauma was defined
as any kind of injury or infected wound. Immunosuppression was
defined as the use of immunosuppressive therapy for autoimmune
disease, chemotherapy or radiation therapy for neoplasia, use of
glucocorticoids, presence of leukemia or lymphoma, HIV-infec-
tion, or splenectomy.
Microbiological testing
Species identification was done using standard microbiological
methods (microscopy, culture characteristics, and oxidase reac-
tion), the API-20NE system (bioMe ´rieux, Marcy l’Etoile, France)
and the automated Vitek 2 system (bioMe ´rieux). Antimicrobial
susceptibility was tested for one S. maltophilia isolate per patient
with the agar dilution method. The isolates had been kept frozen
at 280uC at the microbiological laboratory of the hospital. The
agents tested included ceftazidime, ticarcillin/clavulanic acid,
amikacin, gentamicin, netilmicin, tobramycin, chloramphenicol,
ciprofloxacin, colistin, tetracycline, and trimethoprim/sulfameth-
oxazole. The results were interpreted according to the Clinical and
Laboratory Standards Institute (CLSI) criteria [12]. For agents
that specific CLSI criteria for S. maltophilia had not been published,
the relevant criteria for non-Enterobacteriaceae were used.
Specifically for colistin, a minimum inhibitory concentration
(MIC) #2 mg/L was considered to denote susceptibility, while
an MIC $4 mg/L was considered to denote resistance. Escherichia
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were
used as quality control strains.
Treatment
Empirical antimicrobial therapy was defined as the one
administered from the beginning of the index infectious episode
up to the first isolation of S. maltophilia. Targeted antimicrobial
therapy was defined as the one administered soon after the first
culture results yielding S. maltophilia became available. Only the
antimicrobial agents that target non-fermenting Gram-negative
bacilli with the addition of trimethoprim/sulfamethoxazole were
considered of clinical relevance to the treatment of S. maltophilia
infection and were included in this data analysis. Monotherapy
was defined as treatment with only one of these agents.
Appropriate antimicrobial therapy was defined as the administra-
tion of a regimen that included at least one agent to which the
index S. maltophilia isolate was susceptible. Resistance to other
agents of the same class as well as intrinsic antimicrobial resistance
of S. maltophilia was taken into consideration for the agents that
were not tested [13].
Patient outcome
The primary outcome for the studied patients was the all-cause,
in-hospital mortality. Mortality was considered to be infection-
related, when the clinical signs and symptoms of the S. maltophilia
infection had not resolved at the time of death and the infection
directly contributed to death. Cure was defined as the resolution of
all symptoms and signs of the infection.
Statistical analysis
The baseline patient characteristics and treatment parameters
were tested for their association with all-cause, in-hospital
mortality, using the t-test, the Mann-Whitney U test, or the
Fischer’s exact test for normally distributed continuous variables,
non-parametric continuous variables, and dichotomous variables,
respectively. The one-sample Kolmogorov-Smirnov test was used
to test the continuous variables for normality. Any variable with a
significant association with mortality in the univariate analysis was
entered in a multivariate, forward, stepwise (likelihood ratio),
logistic regression model. A p value#0.05 was considered to
denote statistical significance. All analyses were performed using
the SPSS v. 17 software platform (SPPS Inc, Chicago, IL, USA).
Results
Baseline patient characteristics
Sixty-eight patients with S. maltophilia infection (median age:
70.5 years; 64.7% male) were identified as eligible for inclusion in
our study. Four (5.9%) of the 68 included patients developed the
index S. maltophilia infection while they were outpatients. In all of
these 4 patients, the infection was healthcare-associated; 3 had
chronic renal failure and the remaining patient had a hematolog-
ical malignancy. Thirty-six (52.9%) of the 68 included patients
were being hospitalized in medical departments (of which 16 in the
hematology or oncology department), 18 (26.5%) were being
hospitalized in surgical departments, and the remaining 14
(20.6%) were being hospitalized in the ICU, when the episode
of S. maltophilia infection occurred. All of the included patients had
underlying comorbid conditions, except for 3 with S. maltophilia
keratitis related to the use of contact lenses. The most frequent
underlying comorbidity was cardiac disease and malignancy (each
observed in 26 [38.2%]), followed by pulmonary disease (in 21
[30.9%]). No patient had underlying cystic fibrosis. A recent or a
concurrent infection was noted for 21 patients (30.9%), at the time
that the index S. maltophilia infection developed. Forty-five (66.2%)
of the included patients were immunocompromised, while the
majority of those (31 [68.9%]) were receiving treatment with
S. maltophilia Hospital-Wide Infections
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37375glucocorticoids. Additional data for the baseline characteristics of
the studied patients are presented in Table 1.
Types of infection attributed to S. maltophilia
The main type of infection associated with S. maltophilia was
respiratory tract infection, that was observed in 37 (54.4%) of the
included patients; the lower respiratory tract was involved in all of
the above patients, except for one who had a deep neck space
infection. Eleven (16.2%) patients had a bloodstream infection, in
4 of which it was central venous catheter-related. Seven (10.3%)
patients had a skin/soft tissue infection, 6 (8.8%) patients had an
intra-abdominal infection (peritonitis and cholecystitis in 3 patients
each), 4 (5.9%) had an ocular infection, and the remaining 3
(4.4%) patients had a urinary tract infection.
Microbiological characteristics
The 68 included patients provided a total of 81 culture
specimens from which S. maltophilia was isolated. Sixty-one
(89.7%) patients provided a single positive culture specimen for
S. maltophilia, 5 (7.4%) patients provided multiple positive culture
specimens of the same type, and the remaining 2 (2.9%) patients
provided multiple positive culture specimens of different types.
The specific types of the culture specimens that were provided by
the patients included in our study and from which S. maltophilia
grew are presented in Table 2.
In 45 (66.2%) of the 68 included patients, the index culture from
which S. maltophilia infection was diagnosed was monomicrobial.
Other Gram-negative pathogens were co-isolated in the index S.
maltophilia–positive culture in 20 (29.4%) patients, while Gram-
positive pathogens were co-isolated with S. maltophilia in 14 (20.6%)
patients, and Candida spp. were co-isolated in 7 (10.3%) patients;
detailed relevant data are presented in Table 3. In 24 (35.3%) of
the 68 patients, additional pathogens (other than S. maltophilia)
were isolated in subsequent culture specimens.
In vitro susceptibility
The antimicrobial agents to which the S. maltophilia isolates
exhibited the highest susceptibility were colistin (91.2% suscepti-
bility), trimethoprim/sulfamethoxazole and netilmicin (85.3%
each), chloramphenicol (83.8%), followed by ciprofloxacin,
amikacin, and gentamicin (82.4% each). The susceptibility to
ticarcillin/clavulanic acid and ceftazidime was low (26.5% each);
detailed relevant data are presented in Table 4.
Antimicrobial treatment
Data on the antimicrobial agents administered for the treatment
of the index episode of S. maltophilia infection were available for 55
(80.9%) of the 68 included patients. The classes of antimicrobial
agents most frequently used as empirical therapy, either as
monotherapy or in combination regimens, were the carbapenems
(used in 27.3% of the 55 patients), the fluoroquinolones (25.5%),
and piperacillin/tazobactam (21.8%). The empirical therapy
regimen was deemed inappropriate for 29 (52.7%) patients.
After the first positive culture of S. maltophilia, the antimicrobial
treatment regimen was modified in 23 (41.8%) of the 55 analyzed
patients, including 15 (51.7%) of the 29 patients receiving
inappropriate empirical therapy. The classes of antimicrobial
agents most frequently used as targeted therapy were the
fluoroquinolones (used in 41.8% of the 55 patients), the
carbapenems (29.1%), colistin and piperacillin/tazobactam (in
25.5% of the patients each). Trimethoprim/sulfamethoxazole was
used in 9.1% of the patients. The fluoroquinolones and the
carbapenems were the agents most frequently used as monother-
Table 1. Demographic and baseline characteristics of the 68
evaluated patients with S. maltophilia infection.
n( % )
Demographic characteristics
Age (years), [median (IQR)] 70.5 (54–76)
Sex (male) 44 (64.7)
Department of hospitalization
Medical 36 (52.9)
Hematology/oncology 16/36 (44.4)
Surgical 18 (26.5)
ICU 14 (20.6)
Comorbidity
Cardiac disease 26 (38.2)
Malignancy 26 (38.2)
Pulmonary disease 21 (30.9)
Diabetes mellitus 13 (19.1)
CNS disease 9 (13.2)
Renal disease 9 (13.2)
Trauma 9 (13.2)
Musculoskeletal disease 8 (11.8)
Benign prostate hyperplasia 7 (10.3)
Autoimmune disease 6 (8.8)
Hepatic disease 5 (7.4)
Hypothyroidism 3 (4.4)
Prior/concurrent infection with other pathogens 21 (30.9)
Risk factors for infection
Immunosuppression 45 (66.2)
Glucocorticoid treatment 31/45(68.9)
Indwelling catheter, other than CVC* 32 (47.1)
Malnutrition 30 (44.1)
CVC 28 (41.2)
Urinary catheter 26 (38.2)
Surgery 20 (29.4)
Smoking 19 (27.9)
Prior antibiotic therapy (within 1 month) 13 (19.1)
Transfer from another hospital 8 (11.8)
Obesity 5 (7.4)
Baseline laboratory findings [mean (6SD)]
Hb 13.3 (61.2)
WBC 11.0 (61.25)
Neutrophil/WBC percentage 78.9 (616.2)
Type of infection attributed to S. maltophilia
Respiratory tract infection 37 (54.4)
Bloodstream infection 11 (16.2)
Catheter-related bloodstream infection 4/11 (36.4)
SSTI 7 (10.3)
IAI 6 (8.8)
Peritonitis 3 (4.4)
Cholecystitis 3 (4.4)
Ocular infection 4 (5.9)
UTI 3 (4.4)
Abbreviations: CNS: central nervous system, CVC: central venous catheter, Hb:
hemoglobin, IAI: intra-abdominal infection, ICU: intensive care unit, IQR:
interquartile range, RTI: respiratory tract infection, SD: standard deviation, SSTI:
skin and soft tissue infection, UTI: urinary tract infection.
*Arterial, Swan-Ganz, or nasogastric catheter.
doi:10.1371/journal.pone.0037375.t001
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deemed inappropriate in 20 (36.4%) of the 55 patients. Detailed
data for the antimicrobials used as empirical or targeted therapy in
the 55 analyzed patients are presented in Table 5.
Outcome
Fifty-three (77.9%) of the 68 included patients with S. maltophilia
infection were cured. Twenty-one (80.8%) of the 26 patients who
received appropriate empirical treatment and 23 (79.3%) of the 29
patients who did not receive appropriate empirical treatment were
cured. The median duration of hospitalization was 17 days
(interquartile range: 9–46 days). Ten (14.7%) of the patients died
from any cause during their hospital stay. Death was related to the
S. maltophilia infection in 3 (4.4%) of the 68 patients. Eight of the 10
total deaths and all 3 of the deaths related to the S. maltophilia
infection occurred in patients hospitalized in the ICU.
Risk factors for mortality
In the univariate analyses, the variables that were significantly
associated with increased all-cause in-hospital mortality were
hospitalization in the ICU (p,0.001), presence of a urinary
(p=0.005), central venous (p=0.012), or other indwelling catheter
(p=0.038), higher white blood cell count (p=0.006), co-isolation
of another Gram-negative pathogen in the same culture as S.
maltophilia (p=0.022), use of tigecycline in the empirical regimen
(p=0.011), and use of colistin (p=0.006), tigecycline (p=0.004)
and trimethoprim/sulfamethoxazole (p=0.011) as targeted ther-
Table 2. Types of clinical culture specimens from which S. maltophilia was isolated.
Culture Specimens All specimens (N=74) Polymicrobial culture specimens (N=28)
n( % )
Bronchial secretions/lavage 23 (31.1%) 5 (17.9%)
Sputum 15 (20.3%) 4 (14.3%)
Pus 8 (10.8%) 4 (14.3%)
Blood 7 (9.5%) 3 (10.7%)
Intravascular catheter tip 4 (5.4%) 1 (3.6%)
Urine 4 (5.4%) 3 (10.7%)
Ascitic fluid 3 (4.1%) 3 (10.7%)
Bile 3 (4.1%) 2 (7.1%)
Contact lense 3 (4.1%) 0
Cornea 1 (1.4%) 0
Peritoneal dialysis fluid 1 (1.4%) 1 (3.6%)
Throat swab 1 (1.4%) 1 (3.6%)
Bone 1 (1.4%) 1 (3.6%)
doi:10.1371/journal.pone.0037375.t002
Table 3. Other microorganisms co-isolated with S.
maltophilia in the index culture specimen for the diagnosis of
S. maltophilia infection.
n( % )
None 45 (66.2)
Gram negative 20 (29.4)
Klebsiella pneumoniae 7 (10.3)
Pseudomonas aeruginosa 6 (8.8)
Acinetobacter sp. 4 (5.9)
Achromobacter xylosoxidans 2 (2.9)
Escherichia coli 1 (1.5)
Gram positive 14 (20.6)
Coagulase negative Staphyloccoci 5 (7.3)
Enterococcus faecium 3 (4.4)
Enterococcus faecalis 1 (1.5)
Staphylococcus aureus 1 (1.5)
Sterptococcus sp. 1 (1.5)
Streptococcus pneumoniae 1 (1.5)
Peptosteptococcus pervotii 1 (1.5)
Oerskovia sp. 1 (1.5)
Candida spp. 7 (10.3)
doi:10.1371/journal.pone.0037375.t003
Table 4. Susceptibility pattern of the 68 tested
Stenotrophomonas maltophilia isolates.
Antimicrobial agents S (%) I (%)
Colistin 62 (91.2) 0 (0.0)
Netilmicin 58 (85.3) 4 (5.9)
Trimethoprim/sulfamethoxazole 58 (85.3) 1 (1.5)
Chloramphenicol 57 (83.8) 7 (10.3)
Amikacin 56 (82.4) 3 (4.4)
Ciprofloxacin 56 (82.4) 5 (7.4)
Gentamicin 56 (82.4) 3 (4.4)
Tobramycin 48 (70.6) 1 (1.5)
Tetracycline 47 (69.1) 8 (11.8)
Ceftazidime 18 (26.5) 6 (8.8)
Ticarcillin/clavulanic acid 18 (26.5) 10 (14.7)
I: intermediately susceptible, S: susceptible.
doi:10.1371/journal.pone.0037375.t004
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fluoroquinolones in the empirical therapy regimen (p=0.041) were
associated with decreased mortality. No difference was observed
between patients who survived and those who died regarding the
administration of appropriate empirical therapy [22 of the 45
(48.9%) patients who survived versus 4 of the 10 (40.0%) patients
who died received appropriate empirical therapy, p=0.61] or the
administration of appropriate targeted therapy [29 of the 45
(64.4%) patients who survived versus 6 of the 10 (60.0%) patients
who died received appropriate targeted therapy, p=0.79). In the
multivariate logistic regression model, hospitalization in the ICU
was the only variable that was independently associated with
mortality (odds ratio: 32.0, 95% confidence interval: 5.3–194.9,
p,0.001).
Discussion
In this study, we reviewed 68 cases of S. maltophilia infection that
occurred in a 6-year period at a tertiary-care, university general
hospital, in Crete, Greece. The cases of S. maltophilia infection were
distributed throughout the hospital departments; the majority
occurred in the medical departments (including the hematology
and oncology ones). The main type of infection caused by S.
maltophilia was lower respiratory tract infection, followed by
bloodstream infection, skin or soft tissue infection, and intra-
abdominal infection. Almost all of the cases had one or more
underlying comorbid diseases, the most frequent being cardiac
disease, malignancy, and pulmonary disease (although none had
cystic fibrosis). The majority of the patients were immunosup-
pressed, due to either an underlying disease or drug therapy
(particularly with glucocorticoids). Many patients also had a recent
or concurrent infection with different pathogens or they developed
such an infection during their hospital stay.
The S. maltophilia isolates collected in our study had relatively
high susceptibility to colistin, trimethoprim/sulfamethoxazole,
aminoglycosides, fluoroquinolones, good susceptibility to tetracy-
cline, but low to ticarcillin/clavulanic acid and ceftazidime. Still,
the empirically administered treatment regimen was microbiolog-
ically inappropriate for approximately half of the patients. Even
after the culture results became available, the targeted treatment
regimen remained inappropriate for approximately one third of
the patients. The majority of the patients received combination
antimicrobial therapy. The combination regimens most often
included agents other than trimethoprim/sulfamethoxazole; the
latter was used in less than 10% of the patients. Yet, the all-cause,
in-hospital mortality was relatively low (14.7%) and the infection-
related mortality was only 4.4%. Hospitalization in the ICU was
the only factor that was independently associated with increased
mortality.
The spectrum of the clinical syndromes caused by S. maltophilia
in our study was similar to what has been observed in other
relevant studies [14]. Although the incidence of S. maltophilia
infection may be higher in the ICU, the majority of cases hospital-
wide can occur in other departments, due to the higher number of
patients in these departments [14,15,16]. The affected patients are
those with underlying risk factors, such as serious comorbidity,
prior use of antibiotics, and prolongation of hospital stay [15].
These are also risk factors for infection with other, more frequently
Table 5. Antimicrobial agents used in the empirical and targeted treatment regimens for 55 patients with S. maltophilia infection.
Use in any regimen Use as monotherapy
n( % )
Empirical therapy
Carbapenems 15 (27.3) 6 (10.9)
Fluoroquinolones 14 (25.5) 3 (5.5)
Piperacillin/tazobactam 12 (21.8) 2 (3.6)
Extended-spectrum cephalosporins* 9 (16.4) 2 (3.6)
Aminoglycosides 9 (16.4)‘ 1 (1.8)
Colistin{ 8 (14.5) 0
Tigecycline 5 (9.1) 0
Ticarcillin/clavulanic acid 4 (7.3) 1 (1.8)
Trimethoprim/sulfamethoxazole 3 (5.5) 0
Targeted therapy
Fluoroquinolones 23 (41.8) 5 (9.1)
Carbapenems 16 (29.1) 5 (9.1)
Colistin% 14 (25.5) 0
Piperacillin/tazobactam 14 (25.5) 2 (3.6)
Extended-spectrum cephalosporins* 11 (20.0) 3(5.5)
Aminoglycosides 11 (20.0)‘ 1 (1.8)
Tigecycline 7 (12.7) 0
Ticarcillin/clavulanic acid 6 (10.9) 1 (1.8)
Trimethoprim/sulfamethoxazole 5 (9.1) 0
*3
rd or 4
th generation cephalosporins.
‘4 of the cases refer to ophthalmic use.
%Data refer to intravenously administered colistin.
doi:10.1371/journal.pone.0037375.t005
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was evidenced by the frequent isolation of such pathogens either in
the same culture with S. maltophilia or in subsequent cultures from
the patients included in our study. Many patients received
inappropriate empirical treatment against S. maltophilia, because
piperacillin-tazobactam, extended spectrum cephalosporins or
carbapenems, which are commonly used for the empirical
treatment of nosocomial infections, do not have substantial activity
against S. maltophilia.
Still, the targeted therapy was also inappropriate in approxi-
mately one third of the included patients. The attending physicians
might have chosen to continue administering a regimen to which
the patient had responded, even if this was inactive in vitro. This
could relate to discordance between the in vitro activity and the in
vivo effectiveness of antimicrobial agents or to synergy between the
agents administered in combination regimens [10,16]. Alterna-
tively, the attending physicians might have targeted a presumably
more pathogenic organism in the case of a polymicrobial infection.
Clinicians without experience with S. maltophilia infections might
also erroneously assume that this pathogen is susceptible to agents
such as the carbapenems, piperacillin/tazobactam or extended-
spectrum cephalosporins. This could occur if the antibiogram
reports only refer to the relatively few agents to which S. maltophilia
is not intrinsically resistant and does not specifically state the
resistance to the other agents.
Trimethoprim/sulfamethoxazole has been considered as the
mainstay of therapy against S. maltophilia infections, but this is
primarily based on in vitro susceptibility data rather than clinical
studies [17]. Increasing resistance to trimethoprim/sulfamethox-
azole has been reported by several studies [4,18], mostly related to
the horizontal spread of mobile genetic elements carrying
resistance genes [19,20]. In our study, 13.2% of the isolates were
resistant to trimethoprim/sulfamethoxazole. Although trimetho-
prim/sulfamethoxazole was used in only a minority of patients, the
mortality associated with the S. maltophilia infection was relatively
low. This finding suggests that the alternative to trimethoprim/
sulfamethoxazole treatment regimens used (mainly combination
regimens including a fluoroquinolone, colistin or tigecycline), had
good effectiveness.
The fluoroquinolones are one of the main alternatives to
trimethoprim/sulfamethoxazole for the treatment of S. maltophilia
infections [17]. Although the published relevant clinical experi-
ence refers primarily to ciprofloxacin, levofloxacin and, particu-
larly, moxifloxacin, can have more potent in vitro activity
[7,21,22,23]. In our study, the in vitro susceptibility to ciprofloxacin
was high and a fluoroquinolone was frequently used both as
empirical and targeted therapy. Of note, resistance to the
fluoroquinolones can arise during therapy [10,24,25]. Among
the b-lactams, ticarcillin/clavulanic acid and, secondly, ceftazi-
dime are the ones that can be considered as potential therapeutic
options against S. maltophilia infections, particularly as part of
combination regimens [4,16]. In our study, the susceptibility to
both these agents was rather low, in agreement with other relevant
studies [26].
The issues presented above highlight the need for new
therapeutic options against S. maltophilia infections. According to
our study, colistin and tigecycline could be considered in this
regard. Colistin was the agent to which the S. maltophilia isolates
had the highest susceptibility, and it was used in a substantial
percentage of patients as part of a combination regimen. Variable
findings regarding the in vitro activity of polymyxins against S.
maltophilia have been reported in other studies [16,27,28]. These
differences could relate to differences in the susceptibility testing
methods [28]. We used the agar dilution method which is
generally considered as the reference standard [29]. Geographical
differences in the susceptibility of S. maltophilia isolates to
polymyxins have also been reported [26], while isolates from
patients with cystic fibrosis or patients hospitalized in the ICU can
have higher resistance [6]. S. maltophilia isolates are frequently
susceptible to doxycycline and, particularly, minocycline [30,31].
The susceptibility to tigecycline (a derivative of minocycline) has
also been shown to be high, depending on the interpretative
criteria used [26,30]. Additional clinical experience with the use of
tigecycline against S. maltophilia infections is currently scarce [32].
The aminoglycosides could also be useful as part of combination
regimens for the treatment of S. maltophilia infections. [8]. In our
study, the susceptibility of the S. maltophilia isolates to the
aminoglycosides was high, in contrast with most other studies. S.
maltophilia is considered to have intrinsic resistance to the
aminoglycosides that is mediated by various mechanisms, includ-
ing a chromosomally encoded AAC(69)-Iz enzyme that inactivates
all of the commonly used aminoglycosides, except gentamicin
[33]. This enzyme was not present, however, in 33% of 65 isolates
in one study, which was associated with substantially low MICs
[34].
In our study, both the crude and the infection-related mortality
of S. maltophilia infection were relatively low. The relevant data in
the literature are rather conflicting, but there are studies reporting
considerably high attributable mortality of S. maltophilia infection
[35]. Our study did not include a control group of patients without
S. maltophilia infection, so we could not formally assess the
percentage of deaths attributed to the underlying comorbid
conditions. The low mortality observed in our study could relate
to the fact that the majority of the patients were hospitalized in
other hospital departments than the ICU [36,37]. Hospitalization
in the ICU at the time that S. maltophilia infection occurred was the
only factor that was independently associated with mortality. This
highlights the importance of the severity of the underlying risk
factors for the prognosis of patients with S. maltophilia infection. We
did not analyze indexes of the severity of clinical status in this
regard, because these are not commonly recorded in patients not
hospitalized in the ICU. Our study also included patients with any
type of infection caused by S. maltophilia, some of which may be
associated with a favorable prognosis.
The main limitation of our study is that the differentiation
between colonization and infection with S. maltophilia is not always
be accurate, particularly in the context of a retrospective study
[14,15]. The pathogenic role of S. maltophilia has been debatable,
although it is increasingly being recognized as an important
pathogen in patients with underlying comorbidity [7]. The
pathogenic role of S. maltophilia particularly in polymicrobial
infections, which constituted a considerable percentage in our
study, is also difficult to be ascertained. Other more virulent
pathogens may be more important in this regard, and, in any case,
polymicrobial infections can have a poorer prognosis [38].
Evaluating the microbiological outcome of S. maltophilia infections
would be useful to assess the value of different combination
regimens, particularly in the case of polymicrobial infections.
In the above context, it is difficult to reliably estimate the clinical
effectiveness of the specific antimicrobial agents used for the
treatment of S. maltophilia infections in our study. Most of the
patients received combination antimicrobial therapy. In addition,
certain antimicrobial agents might be more or less likely to be used
in ICU patients who have a poorer prognosis, which might explain
the univariate associations seen between these agents and
mortality.
In conclusion, S. maltophilia infection can occur in patients with
various types of underlying comorbidity and risk factors in the
S. maltophilia Hospital-Wide Infections
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infection in terms of all-cause mortality can be favorable, except
for the patients hospitalized in the ICU. The fluoroquinolones, or
potentially colistin and tigecycline, could be useful alternative
treatment options to trimethoprim/sulfamethoxazole, mainly as
part of combination regimens.
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